The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Clin Liver Dis. 2018;11:81–81.

Blond E, Disse E, Cuerq C, Drai J, Valette P-J, Laville M, Thivolet C, Simon C, Caussy C. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia. 2017;60:1218–22.

Article  CAS  PubMed  Google Scholar 

Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, Zheng M-H, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao J-H, Hamid S, Cua IH, Chan W-K, Payawal D, Tan S-S, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919.

Article  PubMed  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour J-F, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan J-G, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng M-H, Fouad Y, Chan W-K, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9.

Article  PubMed  Google Scholar 

Brunt EM, Wong VWS, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri B, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1.

Kendall TJ, Jimenez-Ramos M, Turner F, Ramachandran P, Minnier J, McColgan MD, Alam M, Ellis H, Dunbar DR, Kohnen G, Konanahalli P, Oien KA, Bandiera L, Menolascina F, Juncker-Jensen A, Alexander D, Mayor C, Guha IN, Fallowfield JA. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2023.

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bedossa P, Poitou C, Veyrie N, Bouillot J-L, Basdevant A, Paradis V, Tordjman J, Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–9.

Article  PubMed  Google Scholar 

Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 2019;70:531–44.

Article  PubMed  Google Scholar 

Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:1388–9.

Article  CAS  PubMed  Google Scholar 

Wang Y-D, Wu L-L, Qi X-Y, Wang Y-Y, Liao Z-Z, Liu J-H, Xiao X-H. New insight of obesity-associated NAFLD: dysregulated “crosstalk” between multi-organ and the liver? Genes Dis. 2023;10:799–812.

Article  CAS  PubMed  Google Scholar 

Huang W, Wang G, Xia Y, Xiong Z, Ai L. Bile salt hydrolase-overexpressing Lactobacillus strains can improve hepatic lipid accumulation in vitro in an NAFLD cell model. Food Nutr Res. 2020;64.

Chandrasekaran VRM, Hsu D-Z, Chien S-P, Liu M-Y. Co-exposure of arsenic and iron causes hepatic injury: a tale of two hits. Epidemiology. 2009;20:S125–S125.

Article  Google Scholar 

Cheng C, Zhuo S, Zhang B, Zhao X, Liu Y, Liao C, Quan J, Li Z, Bode AM, Cao Y, Luo X. Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer. Int J Biol Sci. 2019;15:1654–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191–207.

Article  CAS  PubMed  Google Scholar 

Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, Abate ML, Gambino R, Cassader M, Bugianesi E, Gastaldelli A. Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatology. 2018;67:145–58.

Article  CAS  PubMed  Google Scholar 

Masoodi M, Gastaldelli A, Hyotylainen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour J-F, Oresic M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18:835–56.

Article  PubMed  Google Scholar 

Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids. 2015;47:603–15.

Article  CAS  PubMed  Google Scholar 

Gaggini M, Carli F, Rosso C, Younes R, D'Aurizio R, Bugianesi E, Gastaldelli A. Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease. Int J Mol Sci. 2019;20.

Grzych G, Vonghia L, Bout M-A, Weyler J, Verrijken A, Dirinck E, Curt MJC, Van Gaal L, Paumelle R, Francque S, Tailleux A, Haas JT, Staels B. Plasma BCAA changes in patients with NAFLD are sex dependent. J Clin Endocrinol Metab. 2020;105:2311–21.

Article  Google Scholar 

Trico D, Biancalana E, Solini A. Protein and amino acids in nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2021;24:96–101.

Article  CAS  PubMed  Google Scholar 

Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS. The human serum metabolome. Plos One. 2011;6.

Petrus P, Lecoutre S, Dollet L, Wiel C, Sulen A, Gao H, Tavira B, Laurencikiene J, Rooyackers O, Checa A, Douagi I, Wheelock CE, Arner P, McCarthy M, Bergo MO, Edgar L, Choudhury RP, Aouadi M, Krook A, Ryden M. Glutamine links obesity to inflammation in human white adipose tissue. Cell Metab. 2020;31:375.

Article  CAS  PubMed  Google Scholar 

Crunkhorn S. Type 2 diabetes: targeting glutamine metabolism. Nat Rev Drug Discovery. 2018;17:316–316.

PubMed  Google Scholar 

Simon J, Martinez-Chantar ML, Delgado TC. Glutamine, fatty liver disease and aging. Aging. 2021;13:3165–6.

Article  PubMed  PubMed Central  Google Scholar 

Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017;3:169–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chashmniam S, Ghafourpour M, Farimani AR, Gholami A, Ghoochani BFNM. Metabolomic biomarkers in the diagnosis of non-alcoholic fatty liver disease. Hepat Mon. 2019;19.

Kaikkonen JE, Wuertz P, Suomela E, Lehtovirta M, Kangas AJ, Jula A, Mikkilae V, Viikari JSA, Juonala M, Roennemaa T, Hutri-Kaehoenen N, Kaehoenen M, Lehtimaeki T, Soininen P, Ala-Korpela M, Raitakari OT. Metabolic profiling of fatty liver in young and middle-aged adults: cross-sectional and prospective analyses of the young finns study. Hepatology. 2017;65:491–500.

Article  CAS  PubMed  Google Scholar 

Santos DOR, Cardoso DSG, Lima DCL, de Sousa Cavalcante ML, Silva MS, Cavalcante Martins AK, Severo JS, de Melo Sousa FB, Pacheco G, Alves Pereira EH, NobreSoares LM, Medeiros Rolim JV, Lima-Junior RC, dos Santos AA, Tolentino M. L-glutamine and physical exercise prevent intestinal inflammation and oxidative stress without improving gastric dysmotility in rats with ulcerative colitis. Inflammation. 2021;44:617–32.

Article  PubMed  Google Scholar 

Chakravarthy MV, Waddell T, Banerjee R, Guess N. Nutrition and nonalcoholic fatty liver disease current perspectives. Gastroenterol Clin N Am. 2020;49:63.

Article  Google Scholar 

Stojanovic O, Altirriba J, Rigo D, Spiljar M, Evrard E, Roska B, Fabbiano S, Zamboni N, Maechler P, Rohner-Jeanrenaud F, Trajkovski M. Dietary excess regulates absorption and surface of gut epithelium through intestinal PPARalpha. Nat Commun. 2021;12:7031–7031.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Stojanović O, Altirriba J, Rigo D, Spiljar M, Evrard E, Roska B, Fabbiano S, Zamboni N, Maechler P, Rohner-Jeanrenaud F, Trajkovski M. Dietary excess regulates absorption and surface of gut epithelium through intestinal PPARα. Nat Commun. 2021;12:7031.

Article  ADS  PubMed  PubMed Central  Google Scholar 

Chaudhry KK, Shukla PK, Mir H, Manda B, Gangwar R, Yadav N, McMullen M, Nagy LE, Rao R. Glutamine supplementation attenuates ethanol-induced disruption of apical junctional complexes in colonic epithelium and ameliorates gut barrier dysfunction and fatty liver in mice. J Nutr Biochem. 2016;27:16–26.

Article  CAS  PubMed  Google Scholar 

Abboud KY, Reis SK, Martelli ME, Zordao OP, Tannihao F, de Souza AZZ, Assalin HB, Guadagnini D, Rocha GZ, Saad MJA, Prada PO. Oral glutamine supplementation reduces obesity, pro-inflammatory markers, and improves insulin sensitivity in DIO wistar rats and reduces waist circumference in overweight and obese humans. Nutrients. 2019;11.

Bock PM, Krause M, Schroeder HT, Hahn GF, Takahashi HK, Schoeler CM, Nicoletti G, ZavarizeNeto LD, Lavina Rodrigues MI, Bruxel MA, Homem de Bittencourt PI. Oral supplementations with L-glutamine or L-alanyl-L-glutamine do not change metabolic alterations induced by long-term high-fat diet in the B6.129F2/J mouse model of insulin resistance. Mol Cell Biochem. 2016;411:351–62.

Article  CAS  PubMed  Google Scholar 

Olaniyi KS, Olatunji LA. Inhibition of pyruvate dehydrogenase kinase-4 by L-glutamine protects pregnant rats against fructose-induced obesity and hepatic lipid accumulation. Biomed Pharmacother. 2019;110:59–67.

Article  CAS  PubMed  Google Scholar 

Qiu J, Yue F, Zhu P, Chen J, Xu F, Zhang L, Kim KH, Snyder MM, Luo N, Xu H-W, Huang F, Tao WA, Kuang S. FAM210A is essential for cold-induced mitochondrial remodeling in brown adipocytes. Nat Commun. 2023;14:6344.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531–43.

Article  CAS  PubMed  Google Scholar 

Torres-Villalobos G, Hamdan-Perez N, Tovar AR, Ordaz-Nava G, Martinez-Benitez B, Torre-Villalvazo I, Moran-Ramos S, Diaz-Villasenor A, Noriega LG, Hiriart M, Medina-Santillan R, del Carmen C-H, Mendez-Sanchez N, Uribe M, Torres N. Combined high-fat diet and sustained high sucrose consumption promotes NAFLD in a murine model. Ann Hepatol. 2015;14:540–6.

Article  CAS  PubMed  Google Scholar 

Wu T, Little TJ, Bound MJ, Borg M, Zhang X, Deacon CF, Horowitz M, Jones KL, Rayner CK. A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes. Diabetes Care. 2016;39:511–7.

Article  CAS